Friday, October 30, 2015

Teresa butler wasfiredfromnassau otB



For not ringing the doorbells for Tom suozzi, sued in federal court and won and buried the bodies under a protective order that the us attorney has it yet looked at


Ahmad is the choice for town clerk
Nasrin Ahmad
The Herald encourages Town of Hempstead voters to return Nasrin Ahmad to the town clerk’s seat. She is, far and away, the most qualified candidate for the job.
Considering the sheer volume of important paperwork that flows through the clerk’s office — building permits, marriage licenses, birth and death certificates, zoning ordinances — organization and synchronization are paramount. And with 17 years of experience in the office, Ahmad has proved that she is more than capable of handling it.
A native Ugandan who was raised in England and speaks four languages, she has taken steps in her two years-plus in the top job of clerk to expand transparency, improve technology and increase accessibility. She extended the office’s hours on Thursdays for those with full-time jobs who cannot make it there in the afternoon. She has pushed to make more forms available online. And she has diversified her staff so it can translate documents for non-English speakers. We strongly urge Ahmad to continue making the office a more user-friendly place.
Her Democratic challenger, Dino Amoroso, is also an immigrant — born in Italy, he has lived in Venezuela and Switzerland as well — who speaks four languages. An attorney and a former president of Nassau Off Track Betting, Amoroso says he would take even larger steps to increase transparency in the clerk’s office.
But it’s worth noting that, as a former deputy district attorney in Brooklyn under Charles Hynes, he was included in a corruption probe by the New York City Department of Investigation, which accused the office of illegally using government money for campaign purposes.
Amoroso called the allegations baseless and said that the probe was politically motivated — the lead investigator for the DOI, he said, once lost a district attorney race to Hynes. Nonetheless, we believe his mere association with an ethics scandal disqualifies him to run for an office that must safeguard documents containing town residents’ personal and private information.
Ahmad, who has a warm and welcoming presence, is a first-rate clerk and has taken steps to move the office into the 21st century. We urge residents to give her another term.

Comments

2 comments on this story | Please log in to comment by clicking here
Felix Procacci
Ahmad does not believe in Free Speech and has regularly violated the open meetings law (and the 1st Amendment), see https://www.youtube.com/watch?v=4xMVJ7Qb5_M.

And there are many other videos showing Ahmad and other Town Clerk workers giving less speaking time to some residents based on the content of their statement.

The LIHerald editors know about this, because I told them and showed them the evidence but the
LIHerald receives too much money from the Hempstead Town Government to be objective reporters of the News.
2 days ago | Report this
Felix Procacci
NOTE : Kate Murray has been associated with scandals during her tenure as Town Supervisor (in the building dept. and the Animal Shelter) yet the LIHerald has always endorced her. The LIHerald receives too much money from the Hempstead Town Government to be objective reporters of the News.

Vote for Dino Amoroso, and NEVER listen to the editors of Newspaper that makes their editorial choices based on how much money that candidate can send their way.

PERFECT EXAMPLE : Two years ago, the LIHerald felt that Jasmine Garcia was over qualified for the Town Clerk position and despite this, still endorsed Ahmad. DOES THAT MAKE ANY SENSE?

Monday, October 12, 2015

Support mass murder


Shoot Bcg 
And then ponder mass murder

Pubmed.org RISTORI+ Bcg

Pubmed.org faustman DL

Faustmanlab.org

Uspto.gov faustman inventor search

Mass general is the assignee of faustman's patents and mass general wants you dead impaired or ....
Else mass general would see that Bcg is available to all who suffer rot and seek a better lifeperhaps tsarnaev suffered from ms and was simply mad as hell?





Roche said it expects to meet with regulators in the U.S. and Europe in next year’s first quarter to discuss filing applications for approval of the drug.ENLARGE
Roche said it expects to meet with regulators in the U.S. and Europe in next year’s first quarter to discuss filing applications for approval of the drug. PHOTO: BLOOMBERG NEWS
Roche Holding AG’s Genentech unit said its experimental drug ocrelizumab proved effective in three late-stage studies against multiple sclerosis, potentially heralding an important new treatment option for the debilitating disease.
In two of the studies, which included 1,656 patients with relapsing multiple sclerosis, the most common form of the condition, ocrelizumab proved superior to the commonly used drug, Rebif, in reducing the annual rate of relapse of major symptoms and other measures of the status of the disease, Roche said.
Fewer than 10% of patients had serious side effects on either drug, the company said.
In the third trial, which studied 732 patients with primary progressive multiple sclerosis, the drug was more effective than a placebo in reducing the progression of clinically disabling disease, the company said. The rate of serious adverse events, including serious infections was similar in each group—just over 20%. It marked the first time a drug has shown a benefit in this more serious form of multiple sclerosis in a major trial, researchers said.
Roche hasn’t yet published full results from the studies, which were sponsored by Roche and its Genentech unit. Results will be presented on Friday and Saturday at a meeting of the European Committee for Treatment and Research in Multiple Sclerosis, in Barcelona.
“This is potentially a big deal for our patients,” said Stephen Hauser, chief of neurology at the University of California San Francisco School of Medicine and a leader of the two studies in relapsing multiple sclerosis.
Roche said it expects to meet with regulators in the U.S. and Europe in next year’s first quarter to discuss filing applications for approval of the drug.
Lawrence Steinman, professor of neurology at Stanford University called the findings “a signal advance” for the estimated 15% of patients with the primary progressive form of the disease for whom “so far nothing has worked.”
But for relapsing multiple sclerosis, he said, the ocrelizumab data were in line with some of the 13 other “high efficiency” drugs already on the market. Dr. Steinman, who wasn’t involved with the new studies, said ocrelizumab’s role would likely depend in part on long-term experience with several thousand patients to determine whether the drug is linked to the kind of rare but serious opportunistic infections associated with some of the other medicines.
Multiple sclerosis afflicts more than 250,000 people in the U.S. and more than 2.3 million people world-wide. A result of the body’s own immune system’s attack on myelin sheaths that coat nerve fibers, it typically strikes between the ages of 20 and 40, and affects women more commonly than men. It disrupts transmission of signals between the brain and spinal cord and other parts of the body and is marked by such symptoms as fatigue, muscle weakness, cognitive difficulties and, in some advanced cases, paralysis below the waist.
Many of the other drugs on the market have been especially effective against the relapsing form of the disease, and slowed development of progressive multiple sclerosis, Dr. Hauser said. But even with the new therapies “more than half of our patients 10 years later are worse,” he said.
Currently, because of safety concerns over the more effective treatments, many doctors wait until later in the course of the disease to use them.
Assuming it clears regulatory hurdles, the new drug offers an option of using a “highly effective therapy” early while being “reasonably confident” about its safety, he said.
Ocrelizumab, administered by infusion every six months, targets a protein called CD20 on the surface of immune-system B cells, which Dr. Hauser said trigger an inflammatory process that attacks myelin. His research has played a key role in identifying B cells as a major player in multiple sclerosis, a finding contrary to long-held beliefs about the disease.
Dr. Hauser highlighted one result as especially encouraging for the new drug. While acute relapses typically happen perhaps once a year in the relapsing form of the disease, magnetic resonance imaging studies have shown that bursts of inflammatory attacks on myelin are much more frequent, he said. In the relapsing disease studies, the drug reduced such bursts by 94% and 95% respectively, he said.
“This comes quite close to turning off inflammation” in the myelin sheaths, he said.
Write to Ron Winslow at ron.winslow@wsj.com

Thursday, October 8, 2015

Health.com ignorant or stupid?





11 Symptoms Used to Diagnose Lupus

 By health.com of Health.com |Lupus can trigger a variety of brain and nervous system problems, including nonspecific symptoms like anxiety, headaches, and vision problems. However, two additional concrete symptoms make the list: seizures and psychosis, which is a break from reality and can include delusions and hallucinations.<br><br>For less specific symptoms like headaches, it can be difficult to tease apart whether they are caused by lupus, the medications used to treat it, or the stress of living with the disease.

Seizures or psychosis

Lupus can trigger a variety of brain and nervous system problems, including nonspecific symptoms like anxiety, headaches, and vision problems. However, two additional concrete symptoms make the list: seizures and psychosis, which is a break from reality and can include delusions and hallucinations.

For less specific symptoms like headaches, it can be difficult to tease apart whether they are caused by lupus, the medications used to treat it, or the stress of living with the disease.
© Provided by health.com

Ignorant or stupid?

Bet the Selena Gomez  lupus breeders cup

Dear Selena Gomez,

Bcg will treat lupus.


See faustmanlab.org puBmed.org faustman dl









Selena Gomez reveals she has lupus




Selena Gomez Uncovered
Selena Gomez Uncovered 01:05



Story highlights

  • Lupus is an autoimmune disease that attacks healthy organs in the body
  • It strikes mostly women between the ages of 15 and 44
  • Chemotherapy can stop the more aggressive types of lupus
(CNN)Pop singer Selena Gomez has revealed inBillboard that her diagnosis with the autoimmune disease lupus was behind a recent hiatus from the spotlight.
"I was diagnosed with lupus, and I've been through chemotherapy. That's what my break was really about. I could've had a stroke," Gomez told the magazine in a cover story coming out Thursday.
    Rumors swirled around the 23-year-old singer when she canceled part of her tour back in 2013.
    About 1.5 million Americans have lupus, and it strikes mostly women between the ages of 15 and 44.

    What is lupus?

    Lupus is a chronic disease that can affect any part of the body -- typically the skin, joints, blood and kidneys, according to the Lupus Foundation of America. The immune systems of lupus sufferers essentially go haywire, and instead of fighting off viruses and bacteria with antibodies, their bodies create autoantibodies that attack healthy tissue. Symptoms can include fatigue, fever, weight loss, painful joints, rash, hearing loss, anemia, abnormal bloating and mouth ulcers.
    "I locked myself away until I was confident and comfortable again," Gomez told Billboard.
    Gomez's concern about having a stroke is legitimate.
    "There can be an increased risk of ... strokes, blood clotting in the legs or even heart attacks," said Dr. Joan Merrill, medical director of the Lupus Foundation of America.

    Is chemotherapy the normal treatment?

    Treatment depends on the intensity of the disease. Milder cases can be treated with immunosuppressants or anti-inflammatories, such as aspirin or steroids. However, more severe cases can be treated with chemotherapy drugs, the most common being Cyclophosphamide and Methotrexate.
    Chemotherapy "can stop the more aggressive types of lupus very quickly, and people can do very well on it," Merrill said. "The dosages are usually less than what cancer patients take."
    Lupus can come and go -- flaring up and then heading into remission.
    "It's very unpredictable," Merrill said, adding that it's manageable with proper treatment.